Protease Proteosome

While chaperonins assist proteins to fold correctly proteasomes destroy unfolded chains by partial hydrolysis, cutting the chains into a random assortment of pieces from 3 to 30 residues in length with an average length of 8 residues/ Proteasomes destroy not only unfolded and improperly folded proteins but also proteins marked for destruction by the ubiquitin system described in Box 10-C. It has been hard to locate true proteosomes in most bacteria. However, they do contain protease particles with similar characteristics2-1 and archaeons, such as Thermoplasma acidophilum, have proteasomes similar to those of eukaryotes.cc... 

Extracellular barriers (DNA, enzymes, mucus) Paucity of receptors Proteosome-mediated degradation Inhibition of second-strand synthesis Airway clearance, anti-inflammatory, anti-protease pre-treatments Alternate serotypes, targeted capsid mutants Proteosome inhibitors (tripeptides, anthracyclines) Tyrosine kinase inhibitors... 

W., Eds., The Proteosome-Ubiquitin Protein Degradation Pathway, Springer, Berlin, 2002 Saklatvala, J. and Nagase, H., Eds., Proteases and the Regulation of Biological Processes, Portland Press, London, 2003. 

DCI was developed by James C. Powers and coworkers at Georgia Institute of Technology (Harper, J.W., Hemmi, K., and Powers, J.C., Reaction of serine proteases with substituted isocoumarins discovery of 3,4-dichloroisocoumatin, a new general mechanism-based serine protease inhibitor, Biochemistry 24,1831-1841,1985). This inhibitor is reasonably specific, although side reactions have been described. As with the sulfonyl fluorides and DFR the modification is slowly reversible and enhanced by basic solvent conditions and/or nucleophiles. DCI has been used as a proteosome inhibitor. See Rusbridge, N.M. and... 

Proteolysis is another way to control enzymatic activity, although unlike phosphorylation, the change in activity is irreversible. Many proteases are synthesized as inactive precursors (zymogens) that have to be cleaved by proteolysis to become active. These precursors include proteases that are secreted into digestive tracts or lysosomes, the catalytic active P subunits in the eukaryotic 20 S proteosome that are activated by... 

Figure 7 Various transition-state protease inhibitors. Bortezomib is an approved drug for the treatment of multiple myeloma. It is a boronic acid analog that inhibits the proteosome, a threonine protease. The boronic acid moiety can adopt a tetrahedral conformation in the active site. Pepstatin is a peptidyl aspartic acid inhibitor. The reactive statine group binds to the catalytic machinery, and the chiral hydroxyl group of the statine mimics the tetrahedral geometry of the transition state. Idinavir is an approved HIV 1 Protease inhibitor that binds to the active site via a hydroxyethylene transition state isostere. Aldehydes are also transition state analogs, which are susceptible to nucleophilic attack. In cysteine, serine and threonine proteases, this results in a covalent, reversible inhibition mechanism.

---